you are here:

Unichem Laboratories Ltd.

BSE: 506690 | NSE: UNICHEMLAB |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE351A01035 | SECTOR: Pharmaceuticals

BSE Live

Aug 04, 12:21
310.00 -0.50 (-0.16%)
Volume
AVERAGE VOLUME
5-Day
9,077
10-Day
6,645
30-Day
6,668
33,643
  • Prev. Close

    310.50

  • Open Price

    307.20

  • Bid Price (Qty.)

    310.00 (743)

  • Offer Price (Qty.)

    310.25 (161)

NSE Live

Aug 04, 12:21
309.85 -0.45 (-0.15%)
Volume
AVERAGE VOLUME
5-Day
85,228
10-Day
66,724
30-Day
57,772
57,588
  • Prev. Close

    310.30

  • Open Price

    310.00

  • Bid Price (Qty.)

    309.85 (20)

  • Offer Price (Qty.)

    309.95 (542)

Annual Report

For Year :
2019 2017 2016 2015 2014 2013 2011 2010 2009

Chairman's Speech

I hope you would find our performance in the financial year ended March 31, 2007 good. Let me highlight the main points therein. Our Sales/ Income from operations (Gross) grew by 17.7% over the previous year to cross the Rs. 5500 million mark .with profit before tax and before extra-ordinary gains increasing by 29.7% and profit after tax but before extraordinary gains and prior period adjustments increasing by 27.0% to Rs 889.9 million from Rs. 700.5 million in 2005-06. Unichems focus to enhance capital, operational and human productivity has been the key to this achievement. In spite of the pricing pressures, the domestic pharma industry continues to show decent growth rates, led by the chronic therapeutic (lifestyle) segments like cardiovascular, central nervous system and anti-diabetic. Higher awareness and exposure to newer therapies at affordable prices has been the key driver of growth in the chronic/ lifestyle segment. The Indian domestic formulations market is expected to show better growth in the next fiscal as compared to the current year subject to any unforeseen developments taking place in the regulatory environment. Unichem Domestic sales of formulations touched almost Rs. 4000 million. The Company is looking at expanding its domestic portfolio and strengthen its product portfolio in the domestic market through organic and inorganic modes. We believe that our brand and marketing strategies will drive greater penetration and our market share growth across the Indian market, coupled with our focus on costs, are likely to accord us superior returns over the medium term. Our Active Pharmaceutical Ingredients (API) Business recorded a turnover of Rs. 638 million as compared to Rs. 537 million in the previous year. The export market is expected to witness a healthy growth in the coming years due to imminent patent expiries and pro- generic initiatives across the US & Europe. Unichem is also expected to benefit from some of these emerging opportunities in the near future with its expanded capacity and its increased focus of API business approach. Unichems revenues from International Business grew to Rs. 1303.6 million from Rs. 935.9 million in the previous year registering a growth of 39.3% and contributing to 23.1% of total revenues against 19.6% last year. International business of formulations contributed around 75% of the total export turnover and is expected to be the key driver of growth of future. At present, the Company exports both API as well as formulations to more than 60 countries across the continents. Unichem is targeting growth in exports to regulated markets like Europe, USA and fast growing semi-regulated markets like CIS. The Companys strategy is to leverage its competencies in R&D, manufacturing and business development to exploit the increasing opportunities presented by the generic segment in regulated markets. The Company got US PDA approval for its API plant at Roha, Formulation plant at Goa and its first abbreviated new drug approval i.e. ANDA approval in the year under review. Further, the Company continues its focus on high value added branded generics in select markets. In addition, the Company is actively pursuing strategic and marketing alliances with Companies abroad, in addition to the agreements inked with Lannet & Pliva in the US markets. Expansion projects with strong cost-benefit ratio were initiated with a view to further enhance capital productivity. In this direction, Unichem initiated and completed several expansion projects including expansion of its existing manufacturing facility at Baddi (Himachal Pradesh) and upgradation of its API facilities at Roha & Pithampur. Growth is imperative for enterprise success. We are constantly scouting for and evaluating new opportunities of growth that will propel Unichem to the next higher orbit. The Company acquired balance 40% stake in its subsidiary M/s. Niche Generics Ltd. (U.K.) during the year under review making it a wholly-owned subsidiary. You are aware Niche Generics Ltd. is engaged in developing, marketing and distributing generic pharmaceutical products in European markets. Unichem is increasingly investing on enhancing its research and development capabilities to meet its own requirements as well as to provide it as a service to the global industry which is under costs pressure and is looking for outsourcing to low-cost, advanced capability countries like India. None of these endeavours would have been possible without dedicated contribution of our human resources. People are our prime assets. Unichems quest for value creation would not have been possible but for the support that my colleagues and 1 received from all the customers, business associates, shareholders and members of the Board. 1 am grateful to them for their continued confidence in the management. 1 firmly believe that with the solid foundation that has been laid and the global market beckoning us, we will continue to create superior value for all our stakeholders. Warm Regards, Dr. Prakash A. Mody Chairman & Managing Director